###begin article-title 0
HSP60 as a Target of Anti-Ergotypic Regulatory T Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: FJQ AM PC FM IRC. Performed the experiments: FJQ AM. Analyzed the data: FJQ AM PC FM IRC. Contributed reagents/materials/analysis tools: AM PC FM. Wrote the paper: FJQ IRC.
###end p 1
###begin p 2
###xml 600 608 593 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 702 709 691 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
The 60 kDa heat shock protein (HSP60) has been reported to influence T-cell responses in two ways: as a ligand of toll-like receptor 2 signalling and as an antigen. Here we describe a new mechanism of T-cell immuno-regulation focused on HSP60: HSP60 is up-regulated and presented by activated T cells (HSP60 is an ergotope) to regulatory (anti-ergotypic) T cells. Presentation of HSP60 by activated T cells was found to be MHC-restricted and dependent on accessory molecules - CD28, CD80 and CD86. Anti-ergotypic T cells responded to T-cell HSP60 by proliferation and secreted IFNgamma and TGFbeta1. In vitro, the anti-ergotypic T cells inhibited IFNgamma production by their activated T-cell targets. In vivo, adoptive transfer of an anti-ergotypic HSP60-specific T-cell line led to decreased secretion of IFNgamma by arthritogenic T cells and ameliorated adjuvant arthritis (AA). Thus, the presentation of HSP60 by activated T cells turns them into targets for anti-ergotypic regulatory T cells specific for HSP60. However, the direct interaction between the anti-ergotypic T regulators (anti-HSP60) and the activated T cells also down-regulated the regulators. Thus, by functioning as an ergotope, HSP60 can control both the effector T cells and the regulatory HSP60-specific T cells that control them.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 264 267 264 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Elias1">[1]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Elias2">[2]</xref>
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana1">[3]</xref>
###xml 304 307 304 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Elias3">[4]</xref>
###xml 376 379 376 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-LopezGuerrero1">[5]</xref>
###xml 381 384 381 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 386 389 386 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 527 530 527 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Prakken1">[8]</xref>
###xml 532 535 532 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Prakken2">[9]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-deKleer1">[10]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-deKleer2">[11]</xref>
###xml 846 850 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Huurman1">[12]</xref>
###xml 852 856 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Raz1">[13]</xref>
###xml 901 905 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Delaleu1">[14]</xref>
###xml 984 987 981 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 291 296 <span type="species:ncbi:10090">mouse</span>
###xml 371 375 <span type="species:ncbi:10116">rats</span>
###xml 394 400 <span type="species:ncbi:9606">humans</span>
###xml 753 758 <span type="species:ncbi:9606">human</span>
###xml 837 845 <span type="species:ncbi:9606">patients</span>
###xml 957 962 <span type="species:ncbi:9606">human</span>
The 60 kDa HSP molecule (HSP60) has been found to induce the down-regulation of immune inflammation. Vaccination with self-HSP60 or its peptide epitopes can arrest the development of type 1 diabetes (T1DM), spontaneous or induced, in non-obese diabetic (NOD) mice [1], [2], [3] and in other mouse models [4]; HSP60 vaccination can also inhibit adjuvant arthritis (AA) in rats [5], [6], [7]. In humans, spontaneous HSP60-specific T-cell responses are associated with a relatively good prognosis in juvenile rheumatoid arthritis [8], [9], probably due to the activity of HSP60-specific regulatory cells [10], [11]. HSP60-based immuno-regulation is being exploited clinically for the treatment of autoimmune disorders; the administration of a peptide from human HSP60 has been reported to halt beta-cell destruction in newly diagnosed T1DM patients [12], [13] and to halt experimental Sjogren's syndrome [14]. An HSP60 peptide is also being developed to treat human rheumatoid arthritis [7]. Thus is important to characterize the immune regulatory mechanisms triggered by HSP60.
###end p 4
###begin p 5
HSP60 appears to affect immune inflammation by at least two different mechanisms: as a ligand for innate immune receptors and as an antigen recognized by adaptive immune receptors.
###end p 5
###begin p 6
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov1">[15]</xref>
###xml 635 639 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov2">[16]</xref>
###xml 786 787 774 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 791 795 779 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 804 808 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov3">[17]</xref>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 777 782 <span type="species:ncbi:9606">human</span>
HSP60 can control T cells by innate receptor dependent mechanisms. Soluble human HSP60 was found to directly signal human T cells via toll-like receptor 2 (TLR2). The activation of TLR2 dependant signalling on effector T cells has two consequences: First, it inhibits the migration of T cells towards the chemokine SDF-1 - irrespective of their antigen-specificity - and so inhibits the general entry of T cells into inflammatory sites [15]. Second, it down-regulates T-bet, NF-kappaB, and NFAT, and up-regulates GATA-3, leading to decreased secretion of TNFalpha and IFNgamma and enhanced secretion of IL-10 by the responding T cells [16]. In addition to its direct effects on effector T cells, HSP60-triggered activation of TLR2 signalling boosts the suppressive activity of human CD4+CD25high T cells [17]. These innate, TLR-2 mediated effects of soluble HSP60 can down-regulate T-cell dependent inflammation.
###end p 6
###begin p 7
###xml 349 352 345 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana1">[3]</xref>
###xml 354 358 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Elias4">[18]</xref>
###xml 473 476 469 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 478 481 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 634 638 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen1">[19]</xref>
###xml 908 912 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen2">[20]</xref>
###xml 914 918 910 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana4">[21]</xref>
HSP60 can also control T cells by T-cell receptor dependent mechanisms. In T1DM, for example, vaccination with HSP60 epitopes activates HSP60-specific regulatory T cells that affect the T-cell response to disease-associated antigens (insulin, glutamic acid decarboxylase and HSP60 itself) by inducing a shift from the secretion of INFgamma to IL-10 [3], [18]; HSP60 vaccination induces a similar cytokine shift in the response to the mycobacterial antigens that trigger AA [6], [7]. It has been proposed that HSP60-specific regulatory T cells respond to HSP60 expressed and presented by stressed tissue cells at sites of inflammation [19]. According to this view, down-regulation of tissue inflammation is mediated through a by-stander effect - the Th2 cytokines produced at the site by the HSP60-specific T cells down-regulate the Th1 response of adjacent effector T cells reacting to other tissue antigens [20], [21].
###end p 7
###begin p 8
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen3">[22]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Lohse1">[23]</xref>
###xml 463 467 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran1">[24]</xref>
###xml 469 473 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mor1">[25]</xref>
###xml 520 524 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Correale1">[26]</xref>
###xml 526 530 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Stinissen1">[27]</xref>
###xml 559 563 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Lohse1">[23]</xref>
###xml 600 601 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 609 610 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 678 682 652 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Correale1">[26]</xref>
###xml 684 688 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Stinissen1">[27]</xref>
###xml 690 694 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran2">[28]</xref>
###xml 696 700 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Zang1">[29]</xref>
###xml 890 894 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Lohse1">[23]</xref>
###xml 896 900 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mor1">[25]</xref>
###xml 908 912 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran1">[24]</xref>
###xml 513 519 <span type="species:ncbi:9606">humans</span>
We now report an additional mechanism by which HSP60 down-regulates inflammation: activated effector T cells up-regulate HSP60 and present their own HSP60 epitopes to anti-ergotypic regulatory T cells. Anti-ergotypic regulatory T cells recognize peptides derived from molecules - ergotopes - expressed by T cells primarily when they are activated [22], [23]. Thus far, several ergotopes have been defined: the CD25 molecule and the TNFalpha receptor are examples [24], [25]. Anti-ergotypic T cells, detectable in humans [26], [27] and in experimental animals [23], are heterogeneous: they include CD4+ and CD8+ T-cell receptor alphabeta (TCRalphabeta) and TCRgammadelta T cells [26], [27], [28], [29]. Most importantly, anti-ergotypic T cells have been shown to down-regulate damaging autoimmune inflammation in the model autoimmune diseases experimental autoimmune encephalomyelitis (EAE) [23], [25] and AA [24].
###end p 8
###begin p 9
###xml 324 332 324 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 337 344 337 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Here we show that HSP60 fulfils the three defining properties of a T-cell ergotope: activated T cells express HSP60; HSP60 epitopes are presented by T-cell MHC molecules and trigger specific anti-ergotypic T cells; and the HSP60-specific anti-ergotypic T cells can down-regulate pro-inflammatory effects of effector T cells in vitro and in vivo. In other words, HSP60 is an immune regulatory signal produced not only by stressed tissues, but also by activated effector T cells in need of immune regulation.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
DNA vaccination with pHSP60 activates anti-ergotypic responses
###end title 11
###begin p 12
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp60</italic>
###xml 215 218 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Ragno1">[30]</xref>
###xml 403 406 403 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 845 854 845 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1A</xref>
###xml 1156 1165 1156 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1B</xref>
###xml 1327 1336 1327 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1C</xref>
###xml 290 294 <span type="species:ncbi:10116">rats</span>
###xml 555 559 <span type="species:ncbi:10116">rats</span>
###xml 687 691 <span type="species:ncbi:10116">rats</span>
We have reported that DNA vaccination with the hsp60 gene (pHSP60) or with its N-terminal fragments - constructs pI (aa 1-130) or pII (aa 120-240)- induced HSP60-specific T cells and inhibited the development of AA [6], [7]. DNA vaccination with mycobacterial HSP65 (pHSP65) also protected rats against AA [30], but this vaccination was significantly less effective than was vaccination with self-HSP60 [6]. Does protective HSP60 vaccination activate anti-ergotypic reactivity? To approach this question, we studied the anti-ergotypic T-cell responses in rats vaccinated with pHSP60, pI, pII, pHSP65 or pcDNA3, 26 days after the induction of AA. Lymph node cells (LNC) of the vaccinated rats were incubated with irradiated activated or resting A2b T cells, and proliferative responses were measured to different numbers of A2b stimulator cells. Figure 1A shows that vaccination with pHSP60 induced a proliferative anti-ergotypic T-cell response, which was significantly (p<0.05) higher than that induced by pHSP65. Moreover, vaccination with the pI or pII constructs of HSP60 also induced a significant (p<0.05) anti-ergotypic response compared to pcDNA3 (Figure 1B). Using neutralizing antibodies, we found that the anti-ergotypic response induced by DNA vaccination included both MHC-II (RT1.B) and MHC-I restricted T cells (Figure 1C).
###end p 12
###begin title 13
DNA vaccination with HSP60 induces anti-ergotypic T cells.
###end title 13
###begin p 14
###xml 845 846 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 59 63 <span type="species:ncbi:10116">rats</span>
###xml 627 631 <span type="species:ncbi:10116">rats</span>
A and B. Anti-ergotypic proliferative response of LNC from rats vaccinated with pcDNA3, pHSP65 or pHSP60 (A) or pcDNA3, pI or pII (B), taken 26 days after the induction of AA. Proliferative responses are presented as the DeltaCPM+/-SEM of quadruplicate cultures. * p<0.05 compared to the pHSP65 (A) or the pcDNA3 (B) groups. C. Monoclonal antibodies to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to block the anti-ergotypic proliferative response. Results are presented as the percent of inhibition of proliferation+/-SEM of quadriplicate cultures. D. Anti-ergotypic cytokine response of LNC taken from rats vaccinated with pcDNA3, pHSP65, pHSP60, pI or pII 26 days after the induction of AA. IFNgamma (IFNg), TGFbeta1 (TGFb1), IL-10 and IL-4 were quantified in the culture supernatants after 72 hr of stimulation with 105 activated or resting, irradiated, A2b cells per well. The results are presented as pg/ml+/-SEM of triplicate cultures. Three independent experiments produced similar results.
###end p 14
###begin p 15
###xml 138 147 138 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1A</xref>
###xml 294 303 287 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1D</xref>
Note that the pHSP60 DNA vaccine also increased the response to resting A2b T cells, but to a lower extent than to activated A2b T cells (Figure 1A). However, only activated A2b T cells induced cytokine secretion - characterized by secretion of IFNgamma and TGFbeta1, but not of IL-10 or IL-4 (Figure 1D).
###end p 15
###begin title 16
Peptide Hu3 of HSP60 activates an anti-ergotypic response
###end title 16
###begin p 17
###xml 70 73 70 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 156 165 156 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">Figure 2A</xref>
###xml 507 516 507 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">Figure 2B</xref>
###xml 655 664 655 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1C</xref>
###xml 821 830 814 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">Figure 2C</xref>
Vaccination with the HSP60 peptide Hu3 (aa 31-50) can also inhibit AA [7]. Does effective HSP60-peptide vaccination also induce an anti-ergotypic response? Figure 2A shows that vaccination with peptide Hu3 was significantly (p<0.05) more effective in inducing an anti-ergotypic proliferative response than was vaccination with the homologous, immunogenic Mt3 peptide from mycobacterial HSP65. The anti-ergotypic proliferative response induced by peptide Hu3 was also more focused in its MHC-II restriction (Figure 2B); recall that HSP60 DNA vaccination led to anti-ergotypic proliferative responses that included both MHC-I and MHC-II restricted T cells (Figure 1C). The anti-ergotypic T cells induced by Hu3 peptide vaccination secreted IFNgamma and TGFbeta1, but not IL-10 or IL-4 in response to activated A2b T cells (Figure 2C).
###end p 17
###begin title 18
Vaccination with HSP60 peptide Hu3 induces anti-ergotypic T cells.
###end title 18
###begin p 19
###xml 758 759 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 53 57 <span type="species:ncbi:10116">rats</span>
###xml 557 561 <span type="species:ncbi:10116">rats</span>
A. Anti-ergotypic proliferative response of LNC from rats vaccinated with PBS, Mt3 or Hu3 in IFA, taken 26 days after AA induction. Proliferative responses are presented as the DeltaCPM+/-SEM of quadruplicate cultures. * p<0.05 compared to the Mt3 group. B. Monoclonal antibodies to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to block the anti-ergotypic proliferative response. Results are presented as the percent of inhibition of proliferation+/-SEM of quadruplicate cultures. C. Anti-ergotypic cytokine response of LNC taken from rats vaccinated with PBS, Mt3 or Hu3 in IFA, 26 days after AA induction. IFNgamma (IFNg), TGFbeta1 (TGFb1), IL-10 and IL-4 were quantified in the culture supernatants after 72 hr of stimulation with 105 activated or resting, irradiated, A2b cells per well. The results are presented as pg/ml+/-SEM of triplicate cultures. Three independent experiments produced similar results.
###end p 19
###begin title 20
T-cell activation up-regulates HSP60 expression
###end title 20
###begin p 21
###xml 19 28 19 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figures 1</xref>
###xml 33 34 33 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">2</xref>
###xml 858 867 846 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g003">Figure 3A</xref>
The above results (Figures 1 and 2) suggested that the inhibition of AA by HSP60 DNA or peptide vaccination was associated to the induction of anti-ergotypic proliferative and cytokine responses to activated, syngeneic T cells; but do epitopes of HSP60 function as ergotopes? Is HSP60 up-regulated and presented on activated T cells to anti-ergotypic T cells? To study this question, we compared the expression of HSP60 in activated or resting T cells by western blot. LNC were incubated for 1, 2 or 3 days with the T-cell mitogen Con A, or left untreated. Cell lysates were prepared at the end of the incubation, standardized by protein content, and analyzed by western blot for the expression of HSP60. As a positive control for the induction of HSP60, LNC were also heat shocked for 30 minutes at 42degreesC and allowed to recover for 4 hr at 37degreesC. Figure 3A shows that T-cell activation with Con A or heat shock triggered a similar increase in the expression levels of HSP60. No differences in total protein content were seen when the different samples were analyzed by PAGE-SDS (data not shown).
###end p 21
###begin title 22
T-cell activation up-regulates cellular levels of HSP60.
###end title 22
###begin p 23
A. LNC were stimulated with Con A for 24, 48 or 72 hr, subjected to a 30 minutes 42degreesC heat shock (HS) or kept at 37degreesC (None). Cell lysates were prepared and HSP60 expression was analyzed by western blot with specific antibodies, and quantified (in arbitrary units). B. A2b T-cells were stimulated with various concentrations of the target peptide Mt176-90, a control peptide (Mt3) for 72 hr, or with medium alone (None). Cell lysates were prepared and HSP60 expression was analyzed by western blot with specific antibodies, and quantified (in arbitrary units). Two independent experiments produced similar results.
###end p 23
###begin p 24
###xml 160 169 160 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g003">Figure 3B</xref>
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Ferris1">[31]</xref>
We also detected up-regulation of HSP60 following activation of the T-cell clone A2b by its target peptide epitope Mt176-90 but not by the control peptide Mt3 (Figure 3B); no differences in total protein were seen when the samples were analyzed by PAGE-SDS (data not shown). The up-regulation of HSP60 protein is in agreement with previous studies done at the level of mRNA expression [31], and demonstrates that T-cell activation by specific antigen leads to the up-regulation of cellular HSP60.
###end p 24
###begin title 25
Activated T cells stimulate HSP60-specific T cells
###end title 25
###begin p 26
###xml 366 375 366 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figure 4A</xref>
###xml 848 857 848 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figure 4C</xref>
Are HSP60 epitopes actually presented by activated T cells? We studied this question using HSP60-specific T-cell lines as probes for HSP60-epitope presentation, and a control T-cell line specific for MBP. Activated or resting A2b T cells were irradiated to inhibit their proliferation, and their presentation of HSP60 epitopes was probed with the test T-cell lines. Figure 4A shows that the Anti-HSP60 T cells proliferated upon incubation with activated A2b; the response to resting A2b T-cells was significantly lower. The reaction to HSP60 was specific; the Anti-MBP T cells failed to respond to the A2b T cells, irrespective of their state of activation. Thus, only the activated A2b T cells presented HSP60 epitopes recognizable by the Anti-HSP60 line. The proliferation of the Anti-HSP60 line was restricted through the MHC-II/RT1.B molecule (Figure 4C).
###end p 26
###begin title 27
MHC class II-restricted recognition of activated T cells by HSP60-specific T-cells.
###end title 27
###begin p 28
###xml 817 818 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
A. Anti-ergotypic proliferative response of Anti-HSP60 or Anti-MBP T cell lines. Proliferative responses are presented as the DeltaCPM+/-SEM of quadruplicate cultures. B. Anti-ergotypic proliferative response of Anti-p277 or Anti-MBP T cell lines. Proliferative responses are presented as the DeltaCPM+/-SEM of quadruplicate cultures. C. Monoclonal antibodies to MHC-II/RT1.B, MHC-II/RT1.D or MHC-I were assayed for their ability to block the anti-ergotypic proliferative response of the Anti-HSP60 and the Anti-p277 T cell lines. Results are presented as the percent of inhibition of proliferation+/-SEM of quadruplicate cultures. D. IFNgamma (IFNg), TGFbeta1 (TGFb1), IL-10 and IL-4 were quantified in the culture supernatants after 72 hr of stimulation of the Anti-MBP, Anti-p277 or Anti-HSP60 T cell lines with 105 activated or resting, irradiated, A2b cells per well. The results are presented as pg/ml+/-SEM of triplicate cultures. Three to five independent experiments produced similar results.
###end p 28
###begin p 29
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Reizis1">[32]</xref>
###xml 333 350 333 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figures 4A and 4B</xref>
###xml 454 463 454 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figure 4B</xref>
###xml 572 581 572 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figure 4C</xref>
###xml 125 128 <span type="species:ncbi:10116">rat</span>
The 437-60 region of HSP60 (contained in the HSP60 peptide designated p277) is an immunodominant T-cell epitope in the Lewis rat [32]. We could therefore use an Anti-p277 T-cell line to investigate whether activated A2b T cells presented the defined HSP60 peptide epitope p277. Although less than the Anti-HSP60 T-cell line (compare Figures 4A and 4B), the Anti-p277 T cells showed a significant proliferation upon incubation with activated A2b T cells (Figure 4B), but not with resting A2b T cells. This anti-ergotypic proliferative response was MHC-II/RT1.B restricted (Figure 4C). Thus, activated T cells can present a specific epitope of their up-regulated HSP60 molecules - the p277 peptide epitope; that this occurs in the absence of any other APC, suggests that activated T cells can process and present epitopes of their own HSP60. Thus, T-cell presentation of HSP60 can reveal the state of activity of a T cell.
###end p 29
###begin p 30
###xml 199 208 199 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">Figure 4D</xref>
To investigate how the anti-ergotypic response to HSP60 might function, we analyzed the cytokines produced by Anti-HSP60 and Anti-p277 T cells in response to either activated or resting A2b T cells. Figure 4D shows that both the Anti-HSP60 and Anti-p277 T-cells secreted relatively small amounts of IFNgamma and relatively high amounts of TGFbeta1 upon stimulation with activated A2b T cells only. The T cells did not secrete IL-10 or IL-4.
###end p 30
###begin title 31
The activation of HSP60-specific anti-ergotypic T cells requires co-stimulation
###end title 31
###begin p 32
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Sharpe1">[33]</xref>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Azuma1">[34]</xref>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-HakamadaTaguchi1">[35]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran2">[28]</xref>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g005">Figure 5</xref>
###xml 488 492 <span type="species:ncbi:10116">rats</span>
Complete T-cell activation is achieved when TCR-mediated signaling is reinforced by signals originating from co-stimulatory molecules such as CD28. CD28 interacts with CD80 and CD86 molecules displayed on the surface of APC [33]. Activated T cells [34], [35] and activated A2b [28] express CD80 and CD86 molecules on their surface. We therefore studied the need for CD80, CD86 and CD28 in the activation of HSP60-specific T cells by activated T cells. LNC prepared from pHSP60 vaccinated rats, or Anti-HSP60 T cells, were stimulated with irradiated A2b T cells in the presence of blocking antibodies to CD80, CD86 or CD28. Figure 5 shows that incubation with each one of these antibodies produced a significant inhibition in the anti-ergotypic response of HSP60-specific T cells. Hence, co-stimulation by way of CD80, CD86 and CD28 appears to be required for the activation of anti-ergotypic HSP60-specific T cells by activated T cells.
###end p 32
###begin title 33
The activation HSP60-specific anti-ergotypic T cells requires co-stimulation.
###end title 33
###begin p 34
###xml 226 230 <span type="species:ncbi:10116">rats</span>
###xml 232 235 <span type="species:ncbi:10116">LNC</span>
Monoclonal antibodies to CD28, CD80 or CD86, or a control IgG (Control), were assayed for their ability to block the anti-ergotypic proliferative response of Anti-HSP60 T-cells (Line) or of LNC prepared from pHSP60-vaccinated rats (LNC). Results are presented as the percent of inhibition of proliferation+/-SEM of quadruplicate cultures. Three independent experiments produced similar results.
###end p 34
###begin title 35
HSP60-specific anti-ergotypic T cells ameliorate AA
###end title 35
###begin p 36
###xml 223 224 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 454 458 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana5">[36]</xref>
###xml 460 468 460 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g006">Figure 6</xref>
###xml 685 693 685 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g006">Figure 6</xref>
###xml 234 238 <span type="species:ncbi:10116">rats</span>
###xml 333 337 <span type="species:ncbi:10116">rats</span>
If HSP60-specific anti-ergotypic T cells are indeed regulatory, then it should be possible to inhibit inflammatory disease by adoptively transferring them. We tested the effects of Anti-p277 T cells on AA by transferring 107 cells to rats 3 days before the active induction of AA. As a control, we used the Anti-MBP T-cell line. The rats were scored for signs of arthritis, and the hind paw diameter was measured with a caliper on day 26, the peak of AA [36]. Figure 6 shows that the recipients of the Anti-p277 cells showed a significant reduction in the signs of AA, both in terms of arthritis score and of limb swelling. The Anti-MBP T cells had no effect on the progression of AA (Figure 6).
###end p 36
###begin title 37
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
HSP60-specific anti-ergotypic T-cells control arthritogenic T-cells in vivo.
###end title 37
###begin p 38
###xml 73 77 <span type="species:ncbi:10116">rats</span>
###xml 306 310 <span type="species:ncbi:10116">rats</span>
###xml 315 318 <span type="species:ncbi:10116">LNC</span>
A and B. Anti-MBP or Anti-p277 T cells were injected ip into naive Lewis rats and three days later AA was induced. Twenty-six days after AA induction, at the peak of AA, the AA clinical score (A) and the hind paw diameter (B) were determined. The bars represent the mean values +/- SEM for each group of 8 rats. C. LNC were collected on day 26 after AA induction and the secretion of IFNgamma upon stimulation with Mt176-90 was studied. The results are presented as pg/ml+/-SEM of triplicate cultures. Three independent experiments produced similar results. * p<0.05 and ** p<0.005 compared to the Anti-MBP group.
###end p 38
###begin p 39
###xml 174 182 170 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 221 224 217 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 306 310 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-vanEden1">[37]</xref>
###xml 473 476 465 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 478 481 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 648 657 636 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g007">Figure 7C</xref>
###xml 99 103 <span type="species:ncbi:10116">rats</span>
###xml 122 126 <span type="species:ncbi:10116">rats</span>
###xml 505 508 <span type="species:ncbi:10116">LNC</span>
###xml 514 518 <span type="species:ncbi:10116">rats</span>
The arthritogenic T cells that drive AA have a Th1 phenotype. Accordingly, lymph node T cells from rats suffering from AA rats secrete high levels of IFNgamma in response to in vitro stimulation with the Mt176-90 peptide [6], containing the pathogenic 180-88 T-cell epitope of the mycobacterial 65 kDa HSP [37]. The inhibition of AA achieved by vaccination with HSP60 or its peptides is reported to be associated with a reduction in INFgamma production induced by Mt176-90 [6], [7]. We therefore isolated LNC from rats adoptively transferred with Anti-p277 or Anti-MBP T cells, and studied the secretion of IFNgamma upon stimulation with Mt176-90. Figure 7C shows that the transfer of Anti-p277 T cells led to a significant reduction in the secretion of IFNgamma in response to the AA target peptide Mt176-190. Thus, HSP60-specific T cells, demonstrating anti-ergotype activity, down-regulate IFNgamma secretion by the candidate pathogenic T cells at the time they adoptively down-regulate AA.
###end p 39
###begin title 40
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
HSP60-specific Anti-ergotypic T-cells control arthritogenic T-cells in vitro.
###end title 40
###begin p 41
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 0 3 <span type="species:ncbi:10116">LNC</span>
###xml 22 26 <span type="species:ncbi:10116">rats</span>
LNC from Mt immunized rats (2.5x105 per well) were activated with Mt176-90 for 72 hr in the presence of Anti-p277 or Anti-MBP T-cells (5x104 per well). The secretion of IFNgamma was determined by ELISA, the results are presented as pg/ml+/-SEM of triplicate cultures. The differences between the groups were significant (p<0.05) for antigen concentrations higher than 0.1 microg/ml. Three independent experiments produced similar results.
###end p 41
###begin title 42
HSP60-specific anti-ergotypic T cells modulate effector T-cell IFNgamma in vitro
###end title 42
###begin p 43
###xml 143 150 143 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 669 673 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Holoshitz1">[38]</xref>
###xml 806 814 798 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g007">Figure 7</xref>
###xml 931 939 923 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 330 333 <span type="species:ncbi:10116">LNC</span>
###xml 345 349 <span type="species:ncbi:10116">rats</span>
###xml 380 383 <span type="species:ncbi:10116">LNC</span>
###xml 387 391 <span type="species:ncbi:10116">rats</span>
###xml 664 668 <span type="species:ncbi:10116">rats</span>
The results obtained in the AA model demonstrated that anti-ergotypic HSP60-specific T-cells can control effector T cells by adoptive transfer in vivo. To further investigate the effect of HSP60-specific anti-ergotypic T cells, we tested whether these T cells might be able to directly regulate in vitro the IFNgamma secretion of LNC taken from rats on day 26, at the peak of AA. LNC of rats with actively induced AA were prepared and activated with Mt176-90 in the presence of the Anti-p277 anti-ergotypic T-cell line, or in the presence of the control Anti-MBP T-cell line. T cells reactive with Mt176-90 have been shown to transfer AA to irradiated naive Lewis rats [38]. Co-incubation with the Anti-p277 line, but not with the Anti-MBP line, led to a significant decrease in the secretion of IFNgamma (Figure 7). We did not detect a concomitant induction of IL-10 (not shown). Thus, anti-ergotypic T cells can directly control in vitro the arthritogenic T-cell IFNgamma cytokine response.
###end p 43
###begin title 44
HSP60-specific regulators become anergic while regulating activated T cells
###end title 44
###begin p 45
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 150 157 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen3">[22]</xref>
###xml 1070 1078 1070 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g008">Figure 8</xref>
###xml 1494 1503 1490 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g008">Figure 8A</xref>
###xml 1558 1567 1550 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g008">Figure 8B</xref>
###xml 1690 1698 1679 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2100 2104 2089 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen3">[22]</xref>
We have shown in the previous sections that HSP60-specific anti ergotypic T cells can recognize and down-regulate arthritogenic T cells, in vitro and in vivo. However, any regulatory mechanism has to be regulated; uncontrolled down-regulation of immunity would be as detrimental to the organism as uncontrolled autoimmunity [22]. We therefore studied whether the stimulation of HSP60-specific anti-erogotypic T cells by activated T cells might itself affect the regulators. In other words, might the anti-ergotypic HSP60-specific T-cell lines be affected differently by seeing their HSP60 epitopes presented by activated T cells compared to recognizing HSP60 presented by classical APC? To study this possibility, we incubated the Anti-p277 line for 3 days with either irradiated APC and p277 peptide or with irradiated, activated A2b T cells. The Anti-p277 T cells were then recovered from the cultures, maintained for 4 additional days in culture without APC or A2b T cells, and then stimulated with APC and p277 peptide, with mitogenic Con A or immobilized anti-TCR. Figure 8 presents the outcome. It can be seen that the Anti-p277 T cells, following co-culture with APC and p277 could still respond to a second stimulation with APC and p277 or with mitogenic alphaTCR or ConA; however, previously co-culturing the anti-p277 line with activated A2b T cells rendered the Anti-p277 line anergic; the line now failed to proliferate in response to APC and p277 or to either of the two mitogens (Figure 8A). The Anti-p277 T cells could still secrete IFNgamma (Figure 8B) but not TGFbeta1, IL-10 or IL-4, despite their failure to proliferate. The Anti-p277 line cells, however, went on to die in vitro after their exposure to the activated A2b T cells. Thus, it appears that the interaction of anti-ergotypic T-cell lines with their target activated effector T cells leads to anergy and loss of the anti-ergotypic T cells; activated effector T cells and regulator T cells can down-regulate each other. In contrast, anti-ergotypic T cells can be maintained in culture by APC and specific peptide antigen [22].
###end p 45
###begin title 46
Anti-ergotypic HSP60-specific T cells become anergic after interacting with activated T cells.
###end title 46
###begin p 47
Anti-ergotypic Anti-p277 T cells were stimulated for 3 days with irradiated, activated A2b cells (A2b) or with irradiated APC fed with the p277 peptide (APC). The Anti-p277 T cells were maintained for 4 additional days in culture, and stimulated with APC and p277 peptide, Con A or immobilized anti-TCR (alphaTCR) antibodies. T-cell proliferation (A) and IFNgamma (B) release were measured after 3 days. The proliferative responses are presented as the DeltaCPM (+/-SEM) (A), and the IFNgamma as pg/ml+/-SEM (B) of triplicate cultures. Three to five independent experiments produced similar results.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen3">[22]</xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran2">[28]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Chen1">[39]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Hong1">[40]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Zhang1">[41]</xref>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 542 546 542 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 551 552 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 589 593 589 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 598 599 598 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Chen1">[39]</xref>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Hong1">[40]</xref>
###xml 807 808 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 812 816 812 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 821 822 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Chen1">[39]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Hong1">[40]</xref>
###xml 1027 1031 1027 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Chen1">[39]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Hong1">[40]</xref>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Zhang1">[41]</xref>
###xml 1124 1129 <span type="species:ncbi:9606">human</span>
The present study extends the role of HSP60 in immune regulation; HSP60, as we show here, can also function in anti-ergotypic T-cell regulation. Anti-ergotypic T cells have been identified as a population of regulatory T cells expanded by T-cell vaccination regimes [22], [28]. T cell vaccination has shown promising results in clinical trials that studies its potential as a therapy for multiple sclerosis and rheumatoid arthritis [39], [40], [41]. Notably, T cell vaccination induces two types of anti-ergotypic regulatory T cells: CD4+CD25highFoxp3+ regulatory T cells and also CD4+CD25highFoxp3- regulatory T cells [39], [40]. The anti-ergotypic T cells reactive with HSP60 described in this manuscript did not express the transcription factor Foxp3 (data not shown) and are therefore similar to the CD4+CD25highFoxp3- T cells described by Zhang and coworkers [39], [40]. The association of these anti-ergotypic regulatory cells with a beneficial effect of T cell vaccination on multiple sclerosis and rheumatoid arthritis [39], [40], [41], demonstrates the importance of this regulatory cell population as a target for human immunotherapy. The results presented here demonstrate that HSP60 is an ergotope, shedding light on two separate but overlapping issues: the various roles of HSP60 in immune regulation and the nature of anti-ergotypic T regulators.
###end p 49
###begin p 50
###xml 76 79 76 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 81 84 81 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 142 151 142 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figures 1</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">2</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran2">[28]</xref>
###xml 348 356 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figure 1</xref>
###xml 442 450 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">Figure 2</xref>
Vaccination with HSP60 DNA or peptide, previously shown to down-regulate AA [6], [7], can activate various types of anti-ergotypic responses (Figures 1 and 2). Similarly to what we observed for DNA vaccination with the CD25 ergotope [28], DNA vaccination with HSP60 or its fragments induced both MHC-I and MHC-II restricted anti-ergotypic T cells (Figure 1). Hu3 peptide vaccination, conversely, only activated an MHC-II restricted response (Figure 2). Therefore we can conclude that activated T cells process their endogenous HSP60 by both the MHC-I and the MHC-II pathways of antigen presentation. Moreover, our results suggest that the anti-ergotypic T-cell population responsive to HSP60 is heterogeneous, and different methods of HSP60 vaccination (DNA or peptides) might be used to expand particular HSP60-specific anti-ergotypic subpopulations.
###end p 50
###begin p 51
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cresswell1">[42]</xref>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Levine1">[43]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Strawbridge1">[44]</xref>
###xml 1019 1020 1019 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1026 1030 1026 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Jiang1">[45]</xref>
###xml 1142 1143 1142 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1151 1152 1151 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1161 1165 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Jiang2">[46]</xref>
###xml 1167 1171 1167 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Panoutsakopoulou1">[47]</xref>
It is intriguing that ergotopes such as HSP60 and CD25 are presented by MHC-II molecules. Peptides derived from endogenous antigens are usually MHC-I restricted, while MHC-II molecules mainly present peptides provided by the endocytic pathway of antigen processing [42]. The processing and presentation of endogenous antigens via by the MHC-II pathway has been extensively reported and is thought to result from active mechanisms of autophagy operating in T cells [43], [44]. However, the existence of natural anti-ergotypic regulatory T cells reactive with HSP60 differentiates the MHC presentation of an ergotope from the presentation of other self-antigens: activation-triggered expression of HSP60 turns T cells into targets of HSP60-specific anti-ergotypic regulation. It remains to be seen whether HSP60 epitopes are also presented by other, non-classical MHC molecules. Q1a, for example, is a non-classical MHC-I molecule expressed on T cells that can present endogenous epitopes to regulatory T cells of the CD8+ type [45]. These Q1a-mediated interactions have been shown to control EAE through a T-cell network that involves both CD4+ and CD8+ T cells [46], [47]; it is possible that the Q1a regulatory network also includes anti-ergotypic T cells reactive to HSP60.
###end p 51
###begin p 52
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Merbl1">[48]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana6">[49]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana7">[50]</xref>
###xml 414 418 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Ramage1">[51]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen4">[52]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen5">[53]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen1">[19]</xref>
###xml 683 686 683 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Prakken1">[8]</xref>
###xml 688 692 688 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-deGraeffMeeder1">[54]</xref>
###xml 887 891 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Raz1">[13]</xref>
###xml 130 136 <span type="species:ncbi:9606">humans</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 266 271 <span type="species:ncbi:9606">human</span>
###xml 368 374 <span type="species:ncbi:9606">humans</span>
###xml 758 766 <span type="species:ncbi:9606">patients</span>
HSP60 is also a target of natural T and B cell autoreactivity. Natural antibodies to HSP60 are detectable in the serum of healthy humans [48], [49] and mice [50]; the IgG isotype of these antibodies reveals the activation of helper HSP60-specific T cells. Actually, human cord blood contains a high frequency of T cells responsive to HSP60, and repertoires of healthy humans contain T cells reactive to self-HSP60 [51]. The prevalence of autoimmunity to HSP60 suggests that it serves as a component of the immunological homunculus [52], [53], and mediates an anti-inflammatory effect [19]. Indeed, T-cell reactivity to HSP60 is associated with a good prognosis in juvenile arthritis [8], [54], and the administration of a peptide of HSP60 to newly diagnosed patients with T1DM can arrest the autoimmune destruction of beta-cells and induce a Th1 to Th2 shift in the diabetogenic T cells [13]. Autoimmunity to HSP60, naturally acquired or induced by vaccination, bodes well for healthy immune regulation.
###end p 52
###begin p 53
###xml 268 272 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Li1">[55]</xref>
###xml 274 278 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Pestka1">[56]</xref>
###xml 295 304 292 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g001">Figures 1</xref>
###xml 306 307 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g002">2</xref>
###xml 312 313 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g004">4</xref>
###xml 425 429 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Li1">[55]</xref>
###xml 535 542 529 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 544 552 538 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g006">Figure 6</xref>
###xml 558 566 552 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 568 576 562 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g007">Figure 7</xref>
###xml 1035 1043 1022 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g006">Figure 6</xref>
###xml 1231 1234 1218 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 1236 1239 1223 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 1293 1296 1280 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 1681 1685 1668 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov1">[15]</xref>
###xml 1854 1858 1833 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov2">[16]</xref>
###xml 1860 1864 1839 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-ZaninZhorov3">[17]</xref>
###xml 1559 1564 <span type="species:ncbi:9606">human</span>
How might HSP60-specific anti-ergotypic T cells control the arthritogenic T cells? The anti-inflammatory properties of HSP60-specific T cells are thought to rely on a local by-stander effect exerted on other T cells via regulatory cytokines such as IL-10 and TGFbeta1 [55], [56]. We have found (Figures 1, 2 and 4), that the HSP60-specific anti-ergotypic T cells secrete TGFbeta1, a cytokine with immuno-modulatory functions [55]. Indeed, the HSP60-specific anti-ergotypic T cells controlled the activity of arthritogenic T cells both in vivo (Figure 6) and in vitro (Figure 7). We propose that upon recognition of their target HSP60 epitopes within MHC molecules on the surface of activated T cells, the anti-ergotypic T cells can modulate the pro-inflammatory activity of effector T cells via the secretion of TGFbeta1, and perhaps other, yet undetected regulatory cytokines. Note that upon transfer of anti-ergotypic HSP60-specific T cells, we detected a decrease in the activity of the arthritogenic T cells that secrete IFNgamma (Figure 6). However, we did not detect a concomitant increase in the number of IL-10 secretors, as we have previously described upon vaccination with DNA vaccines coding for HSP60 or its fragments [6], [7], or following vaccination with the HSP60 peptide Hu3 [7]. Hence, the participation of HSP60 in anti-ergotypic regulatory networks might only account for some, but not all, of the regulatory activities of HSP60-specific T cells. Indeed, it has been recently shown that HSP60 can have direct anti-inflammatory effects on human T cells which are TLR2-dependant: free HSP60 can inhibit T-cell migration towards the inflammatory chemokine SDF-1A [15] and modify the levels of transcription factors involved in T-cell polarization, leading to decreased secretion of TNFalpha and IFNgamma and enhanced secretion of IL-10 [16], [17].
###end p 53
###begin p 54
###xml 173 181 173 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004026-g008">Figure 8</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran1">[24]</xref>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran2">[28]</xref>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-LaSalle1">[57]</xref>
###xml 1124 1128 1124 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Taams1">[58]</xref>
###xml 1344 1348 1344 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen6">[59]</xref>
###xml 1383 1387 1383 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Cohen3">[22]</xref>
###xml 443 447 <span type="species:ncbi:10116">rats</span>
Finally, the present study indicates that HSP60-specific anti-ergotypic regulatory T cells can be down-regulated as a result of their interaction with their target T cells (Figure 8). Indeed, the induction of a strongly arthritogenic T-cell effector response leading to adjuvant arthritis was found to suppress the anti-ergotypic regulator response; this down-regulation of the regulators by the effectors could be overcome by vaccinating the rats with an ergotope, CD25 [24]. Thus, the magnitude of an immune response can be influenced decisively by a dynamic balance between regulators and effectors [28]. In this light, we can view the complex roles of HSP60 in immuno-regulation: HSP60 facilitates the recognition and control of activated T cells via anti-ergotypic interactions, and this regulatory interaction also down-regulates the activity of the HSP60-specific regulators. The regulatory molecules on activated T cells that down-regulate the anti-ergotypic regulators remain to be discovered; however, it has been reported that mutual interactions between T cells (T-T interactions) can induce T-cell anergy [57], [58]. Thus, the numbers of regulatory T cells reactive to HSP60 might be positively influenced by the presentation of HSP60 by professional APC and negatively influenced by the presentation of HSP60 by activated T cells [59]; regulators, too, need regulation [22].
###end p 54
###begin p 55
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Pockley1">[60]</xref>
In conclusion, our results show that the varied regulatory mechanisms mediated by HSP60 are complex indeed; not only does the immune system use innate and adaptive receptors to respond to HSP60 expressed in situ by the tissues and in body fluids [60], we can now conclude that the immune system uses its own HSP60 expressed on activated T cells as a marker that reflects their functional state and their need of regulation.
###end p 55
###begin title 56
Materials and Methods
###end title 56
###begin title 57
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
Rats
###end title 57
###begin p 58
###xml 13 17 <span type="species:ncbi:10116">rats</span>
###xml 247 251 <span type="species:ncbi:10116">rats</span>
Female Lewis rats were raised and maintained under pathogen-free conditions in the Animal Breeding Center of the Weizmann Institute of Science. Experiments were carried out under the supervision and guidelines of the Animal Welfare Committee. The rats were 1-2 months old at the start of the experiments.
###end p 58
###begin title 59
Antigens, peptides, antibodies and adjuvants
###end title 59
###begin p 60
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M. tuberculosis</italic>
###xml 422 425 422 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Anderton1">[61]</xref>
###xml 622 625 622 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 695 699 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-vanEden1">[37]</xref>
###xml 0 15 <span type="species:ncbi:1773">M. tuberculosis</span>
###xml 17 19 <span type="species:ncbi:1773">Mt</span>
###xml 78 80 <span type="species:ncbi:1773">Mt</span>
###xml 427 437 <span type="species:ncbi:10141">Guinea pig</span>
M. tuberculosis (Mt) strain H37Ra was obtained from Difco (Detroit, MI, USA). Mt purified protein derivative (PPD) was provided by the Statens Seruminstitut (Copenhagen, Denmark). Recombinant mycobaterial 65 kDa HSP (HSP65) was kindly provided by Dr. Ruurd van der Zee (Institute of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht, The Netherlands). Recombinant HSP60 was prepared as described [6]. Guinea pig myelin basic protein (MBP) was purchased from Sigma (Rehovot, Israel). Two HSP65 peptides were used: Mt176-190 (aa 176-190) EESNTFGLQLELTEG [61] and Mt3 (aa 5-24) AYDEEARRGLERGLNALADA [7]. The Mt176-90 peptide used in this work includes the 180-188 epitope [37]. Two peptides derived from HSP60 were used: p277 (aa 437-460) VLGGGCALLRCPALDSLTPANED and Hu3 (aa 31-50) KFGADARALMLQGVDLLADA. Peptides were synthesized by a standard Fmoc procedure, purified by reverse-phase HPLC and their compositions confirmed by aa analysis. Concanavalin A (Con A) was purchased from Sigma. Incomplete Freund's Adjuvant (IFA) was purchased from Difco.
###end p 60
###begin p 61
###xml 34 37 <span type="species:ncbi:10116">rat</span>
###xml 281 287 <span type="species:ncbi:9986">rabbit</span>
###xml 293 298 <span type="species:ncbi:9606">human</span>
A monoclonal antibody reactive to rat TCR (clone R73) was purified by us from the hybridoma. Monoclonal antibodies to MHC class-I (MHC-I), MHC class-II RT1.B (MHC-II/ RT1.B), MHC class-II RT1.D (MHC-II/RT1.D), CD28, CD80 and CD86 were purchased from Serotec (Oxford, UK). Purified rabbit anti-human HSP60 polyclonal IgG antibodies were provided by Dr Gabriel Nussbaum (Department of Immunology, The Weizmann Institute of Science, Israel).
###end p 61
###begin title 62
T-cell lines and clones
###end title 62
###begin p 63
###xml 51 55 51 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Holoshitz1">[38]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-vanEden1">[37]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mimran3">[62]</xref>
###xml 777 781 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Mor2">[63]</xref>
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 155 160 <span type="species:ncbi:9606">human</span>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 200 203 <span type="species:ncbi:10116">rat</span>
###xml 290 295 <span type="species:ncbi:9606">human</span>
###xml 321 324 <span type="species:ncbi:10116">rat</span>
###xml 399 409 <span type="species:ncbi:10141">guinea pig</span>
###xml 561 564 <span type="species:ncbi:10116">rat</span>
T-cell lines were raised and expanded as described [38]. Three Lewis rat T-cell lines were used in our experiments: Anti-HSP60, raised against recombinant human HSP60 (human HSP60 is 97% identical to rat HSP60 at the aa level, data not shown); Anti-p277, raised against the p277 peptide of human HSP60 (96% identical its rat counterpart at the aa level, data not shown) and Anti-MBP, raised against guinea pig MBP. For ergotypic stimulation, we used the A2b T-cell clone, specific for the 180-188 epitope of HSP65 [37]; similar results were obtained when other rat T-cell clones were used as targets (data not shown). A2b expresses MHC-I molecules constitutively and CD80, CD86 [62] and MHC-II molecules (not shown) upon activation, and can present peptide epitopes to T cells [63]. Activated A2b cells were used on day 3 of their stimulation, and resting A2b cells were used on day 14-16 of their rest cycle, unless stated otherwise.
###end p 63
###begin title 64
DNA and peptide vaccination
###end title 64
###begin p 65
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp60</italic>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana3">[7]</xref>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Ragno1">[30]</xref>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The vectors containing the full-length cDNA of the human hsp60 gene (pHSP60) or the cDNA corresponding to aa 1-140 (pI) or aa 130-260 (pII) have been previously described [6], [7]. The vector coding for mycobacterial HSP65 (pHSP65) was kindly provided by Dr. Douglas Lowrie (Medical Research Council, London, UK) [30]. The empty vector pcDNA3 was used as a DNA vaccination control.
###end p 65
###begin p 66
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana5">[36]</xref>
###xml 317 324 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Limulus</italic>
###xml 400 407 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 136 140 <span type="species:ncbi:10116">rats</span>
Plasmid DNA was prepared in large scale and injected after pretreatment with cardiotoxin (Sigma) as previously described [36]. Briefly, rats were vaccinated in the quadriceps three times (on days -40, -26 -12 relative to AA induction) with 150 microg of pcDNA3, pHSP65 or pHSP60. Endotoxin levels were checked by the Limulus amoebocyte lysate assay and found always to be under acceptable levels for in vivo use (less than 0.02 EU/microg DNA).
###end p 66
###begin p 67
###xml 13 17 <span type="species:ncbi:10116">rats</span>
Female Lewis rats were immunized intraperitoneally (ip) with a single dose of 100 microg of peptide emulsified in IFA. AA was induced 12 days after the completion of vaccination with DNA or peptide.
###end p 67
###begin title 68
AA Induction and Assessment
###end title 68
###begin p 69
###xml 88 91 88 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 589 592 589 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
###xml 33 35 <span type="species:ncbi:1773">Mt</span>
AA was induced using heat-killed Mt strain H37Ra (Difco) suspended in IFA, as described [6]. The day of AA induction was designated as day 0. Disease severity was assessed by direct observation of all 4 limbs in each animal. A relative score between 0 and 4 was assigned to each limb, based on the degree of joint inflammation, redness and deformity; thus the maximum possible score for an individual animal was 16. Arthritis was also quantified by measuring hind limb diameter with a caliper. Measurements were taken on the day of the induction of AA and 26 days later, at the peak of AA [6]; the results are presented as the mean+/-SEM of the difference between the values for hind limb diameter taken on days 0 and 26.
###end p 69
###begin title 70
Anti-ergotipic T-cell proliferation assay
###end title 70
###begin p 71
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 551 555 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana8">[64]</xref>
###xml 768 769 754 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 829 830 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 34 37 <span type="species:ncbi:10116">LNC</span>
T-cell lines or lymph node cells (LNC, prepared from inguinal and popliteal lymph nodes) were cultured in quadruplicates, 2.5x105 per well, in round-bottom microtiter wells (Nunc, Roskilde, Denmark). Activated or resting A2b stimulator cells were irradiated (5000 R) and added to the test cultures in 2-fold dilutions, starting from 105 cells per well, with no other APC. Con A (1.25 microg/ml) was used as a positive control for T-cell proliferation, and in some experiments the cells were activated with immobilized anti-TCR antibodies as described [64]. Monoclonal antibodies, 10 microg/ml, were added where indicated to test for MHC restrictions or co-stimulation requirements of the anti-ergotypic T cells. Cultures were incubated for 72 hr at 37degreesC in 7% CO2, and pulsed for the last 16 hr with 1 muCi/well of [methyl-3H]-thymidine (Amersham, Buckinghamshire, UK). The cultures were harvested and cpm were determined using a beta counter. The DeltaCPM was computed as the difference between the mean cpm of wells containing activated or resting A2b stimulator cells to control wells cultured with medium alone.
###end p 71
###begin title 72
Cytokine assays
###end title 72
###begin p 73
###xml 192 195 185 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 330 333 321 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004026-Quintana2">[6]</xref>
Supernatants were collected after 72 hr of stimulation with test antigens or stimulator cells. Pharmingen's OPTEIA IL-10, IL-4 and IFNgamma kits (Pharmingen, San Diego, USA) and the TGFbeta1 Emax(R) ImmunoAssay System (Promega, Madison, USA) were used to quantify cytokine release to culture supernatants, as previously described [6]. The lower limits of detection for the experiments described in this paper were 15 pg/ml for TGFbeta1, IL-10, IL-4 and IFNgamma.
###end p 73
###begin title 74
Western blotting
###end title 74
###begin p 75
Cell lysates of resting or activated T cells were prepared by treatment for 15 minutes in the following lysis buffer: NP40 1%, NaCl 0.9%, Tris 50 mM, EDTA 1 mM, PMSF 0.4 mM, pepstatin A 4 microg/ml, leupeptin 4 microg/ml and aprotinin 4 microg/ml. The lysates were centrifuged for 15 min at 14000 rpm and the protein concentration in the supernatant was determined using a BCA protein assay kit (Pierce, Rockford, IL, USA). The lysates were subjected to PAGE-SDS using a mini-gel apparatus (Bio-Rad Laboratories, Hercules, CA); 100 microg of each sample were loaded per well. Two identical gels were run each time in parallel: one gel was stained with Coomassie Brilliant Blue R-250 according to the manufacturer's protocol (Bio-Rad) and the other was electro-transferred to nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany).
###end p 75
###begin p 76
###xml 84 90 <span type="species:ncbi:9913">bovine</span>
###xml 446 450 <span type="species:ncbi:9925">goat</span>
###xml 456 462 <span type="species:ncbi:9986">rabbit</span>
The nitrocellulose membranes were washed with PBS and then blocked for 1 hr with 2% bovine serum albumin (Sigma), 2.5% milk powder (Bio-Rad), Tris (Sigma) pH 7.5 10 mM, NaCl 150 mM and 0.02% thimerosal (Sigma). After washing with PBS/Tween 20 (PBST; 0.02%, Sigma), the membranes were incubated in blocking solution for 2 hr with HSP60-specific polyclonal antibodies. The membranes were washed with PBST and incubated with a peroxidase-conjugated goat anti-rabbit IgG (Jackson Immuno-Research, West Grove, PA) at a 1/10000 dilution in blocking solution for 1 hr. Finally, the membranes were developed using the Western Blotting Luminol Reagent (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), exposed to X-ray film and quantified using the NIH Image 1.63 program (National Institutes of Health, USA). Size was determined using pre-stained broad-range protein standard markers (Bio-Rad).
###end p 76
###begin title 77
Adoptive transfer of anti-ergotypic T cells
###end title 77
###begin p 78
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 175 178 <span type="species:ncbi:10116">rat</span>
Anti-p277 or Anti-MBP T cells were activated for 3 days in culture. Blast cells were isolated using a LymphoPrep gradient (Nycomed, Oslo, Norway), washed, and 5x106 cells per rat were injected ip. Three days later, AA was induced.
###end p 78
###begin title 79
Statistical significance
###end title 79
###begin p 80
The InStat 2.01 program was used for statistical analysis. Student's t-test and the Mann-Whitney test were carried out to assay significant differences between the different experimental groups.
###end p 80
###begin p 81
We are grateful to Prof. Doug Lowrie for providing us with the pHSP65 vector.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein.
###end article-title 83
###begin article-title 84
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.
###end article-title 84
###begin article-title 85
DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes.
###end article-title 85
###begin article-title 86
The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin.
###end article-title 86
###begin article-title 87
###xml 42 46 <span type="species:ncbi:10116">rats</span>
###xml 62 76 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
Modulation of adjuvant arthritis in Lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein.
###end article-title 87
###begin article-title 88
###xml 59 64 <span type="species:ncbi:9606">human</span>
Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60.
###end article-title 88
###begin article-title 89
###xml 17 22 <span type="species:ncbi:9606">human</span>
DNA fragments of human HSP60 vaccinate against adjuvant arthritis: Identification of a regulatory HSP60 peptide.
###end article-title 89
###begin article-title 90
###xml 18 23 <span type="species:ncbi:9606">human</span>
Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis.
###end article-title 90
###begin article-title 91
###xml 21 26 <span type="species:ncbi:9606">human</span>
T-cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint.
###end article-title 91
###begin article-title 92
###xml 105 110 <span type="species:ncbi:9606">human</span>
The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10.
###end article-title 92
###begin article-title 93
###xml 82 90 <span type="species:ncbi:9606">patients</span>
CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.
###end article-title 93
###begin article-title 94
Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.
###end article-title 94
###begin article-title 95
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
###end article-title 95
###begin article-title 96
Inhibition of experimental Sjogren's syndrome through immunization with HSP60 and its peptide amino acids 437-460.
###end article-title 96
###begin article-title 97
T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors.
###end article-title 97
###begin article-title 98
Heat shock protein 60 inhibits Th1-mediated hepatitis model via innate regulation of Th1/Th2 transcription factors and cytokines.
###end article-title 98
###begin article-title 99
Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling.
###end article-title 99
###begin article-title 100
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens.
###end article-title 100
###begin article-title 101
HSP60 and the Regulation of Inflammation: Physiological and Pathological.
###end article-title 101
###begin article-title 102
Real and artificial immune systems: computing the state of the body.
###end article-title 102
###begin article-title 103
Heat shock proteins as endogenous adjuvants in sterile and septic inflammation.
###end article-title 103
###begin article-title 104
Tregs in T cell vaccination: exploring the regulation of regulation.
###end article-title 104
###begin article-title 105
Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells.
###end article-title 105
###begin article-title 106
###xml 35 39 <span type="species:ncbi:10116">rats</span>
DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.
###end article-title 106
###begin article-title 107
###xml 153 156 <span type="species:ncbi:10116">rat</span>
IL-2 and TNF receptors as targets of regulatory T-T interactions: isolation and characterization of cytokine receptor-reactive T cell lines in the Lewis rat.
###end article-title 107
###begin article-title 108
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD8+ TCR-alpha beta(+) and TCR-gamma delta(+) cells modulate autologous autoreactive neuroantigen-specific CD4+ T-cells by different mechanisms.
###end article-title 108
###begin article-title 109
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Gammadelta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination.
###end article-title 109
###begin article-title 110
Regulatory T cells in autoimmune diseases: anti-ergotypic T cells.
###end article-title 110
###begin article-title 111
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis.
###end article-title 111
###begin article-title 112
###xml 14 18 <span type="species:ncbi:10116">rats</span>
Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65.
###end article-title 112
###begin article-title 113
Mitogen and lymphokine stimulation of heat shock proteins in T lymphocytes.
###end article-title 113
###begin article-title 114
###xml 78 81 <span type="species:ncbi:10116">rat</span>
The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI.
###end article-title 114
###begin article-title 115
The B7-CD28 superfamily.
###end article-title 115
###begin article-title 116
Functional expression of B7/BB1 on activated T lymphocytes.
###end article-title 116
###begin article-title 117
###xml 50 56 <span type="species:ncbi:10090">murine</span>
Expression and co-stimulatory function of B7-2 on murine CD4+ T cells.
###end article-title 117
###begin article-title 118
###xml 88 93 <span type="species:ncbi:9606">human</span>
Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: Immune cross-regulation with the 60-kd heat-shock protein.
###end article-title 118
###begin article-title 119
Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis.
###end article-title 119
###begin article-title 120
###xml 21 25 <span type="species:ncbi:10116">rats</span>
Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II.
###end article-title 120
###begin article-title 121
Vaccination with selected synovial T cells in rheumatoid arthritis.
###end article-title 121
###begin article-title 122
###xml 66 74 <span type="species:ncbi:9606">patients</span>
CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis.
###end article-title 122
###begin article-title 123
###xml 28 33 <span type="species:ncbi:9606">human</span>
MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.
###end article-title 123
###begin article-title 124
Assembly, transport, and function of MHC class II molecules.
###end article-title 124
###begin article-title 125
Unveiling the roles of autophagy in innate and adaptive immunity.
###end article-title 125
###begin article-title 126
Autophagy in MHC class II antigen processing.
###end article-title 126
###begin article-title 127
The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1.
###end article-title 127
###begin article-title 128
T cell vaccination induces T cell receptor Vbeta-specific Qa-1- restricted regulatory CD8(+) T cells.
###end article-title 128
###begin article-title 129
Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes.
###end article-title 129
###begin article-title 130
###xml 8 14 <span type="species:ncbi:9606">humans</span>
Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics.
###end article-title 130
###begin article-title 131
###xml 20 25 <span type="species:ncbi:9606">human</span>
Cluster analysis of human autoantibody reactivities in health and in type 1 diabetes mellitus: a bio-informatic approach to immune complexity.
###end article-title 131
###begin article-title 132
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes.
###end article-title 132
###begin article-title 133
T cell responses to heat-shock protein 60: differential responses by CD4+ T cell subsets according to their expression of CD45 isotypes.
###end article-title 133
###begin article-title 134
The cognitive paradigm and the immunological homunculus.
###end article-title 134
###begin article-title 135
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favorable course of arthritis.
###end article-title 135
###begin article-title 136
Transforming growth factor-beta regulation of immune responses.
###end article-title 136
###begin article-title 137
Interleukin-10 and related cytokines and receptors.
###end article-title 137
###begin article-title 138
###xml 27 32 <span type="species:ncbi:9606">human</span>
Early signaling defects in human T cells anergized by T cell presentation of autoantigen.
###end article-title 138
###begin article-title 139
Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions.
###end article-title 139
###begin article-title 140
T-cell vaccination for autoimmune disease: a panorama.
###end article-title 140
###begin article-title 141
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals.
###end article-title 141
###begin article-title 142
Differential mycobacterial 65-kDa heat shock protein T cell epitope recognition after adjuvant arthritis-inducing or protective immunization protocols.
###end article-title 142
###begin article-title 143
###xml 32 36 <span type="species:ncbi:10116">rats</span>
Anti-ergotypic T cells in naive rats.
###end article-title 143
###begin article-title 144
Angiogenesis-inflammation cross-talk: VEGF is secreted by activated T-cells and induces Th1 polarization.
###end article-title 144
###begin article-title 145
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.
###end article-title 145
###begin p 146
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 146
###begin p 147
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partially supported by grants from the Center for the Study of Emerging Diseases and by the EU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 147

